medigraphic.com
ISSN 0028-3851 (Print)

2022, Number 2

<< Back Next >>

Rev Neurol Neurocir Psiquiat 2022; 50 (2)

Characteristics of chronic migraine after a pericraneal block with local anesthetics and dexamethasone in adults

Villa TF, Domínguez V, Henao LM, Taborda SA, Giraldo YM

Language: Spanish
References: 36
Page: 44-50
PDF size: 167.88 Kb.


ABSTRACT

Introduction: the use of a pericraneal block with local anesthetics has been used as an alternative for some patients with chronic migraine who do not respond to oral therapy. Steroids have been traditionally avoided, but there are no studies that evaluate adverse effects associated with the use of dexamethasone in this procedure. Objective: to observe the changes in pain characteristics and presence of adverse effects in patients with chronic migraine without an adequate response to more than two preventive oral drugs after the first pericraneal block with local anesthetics and dexamethasone. Material and methods: prospective, descriptive cohort during the year 2019-2020 in the Instituto Neurológico de Colombia. Twenty-two patients were observed, comparing the basal pain characteristics, its changes and presence of adverse effects 30 days after the procedure. Results: there was a change in the median of the difference of the average headache intensity (2, CI 95% 0.4-3.6) in the visual analogue scale (p = 0.019) and of the number of migraine days of the month (10, CI 95% 4.5-15.5; p = 0.001). Twenty-four percent of patients reported an adverse effect, all of them mild, and none of them aesthetical. Conclusion: in our cohort, the first pericraneal block with local anesthetics and dexamethasone reduced the median of the difference of headache intensity and of the number of days of the month with headache, without any aesthetic adverse effects for patients.


REFERENCES

  1. Gobel H. The International Classification of Headache Disorders [Internet]. ICHD-3. [Citado 9 de mayo de 2021]. Disponible en: https://ichd-3.org/

  2. Dodick DW. Migraine. Lancet. 2018; 391 (10127): 1315-1330.

  3. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013; 14 (1): 1.

  4. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017; 16 (11): 877-897.

  5. Agosti R. Migraine burden of disease: from the patient's experience to a socio-economic view. Headache. 2018; 58 Suppl 1: 17-32.

  6. Takeshima T, Wan Q, Zhang Y, Komori M, Stretton S, Rajan N et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019; 20 (1): 111.

  7. Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people's life. J Headache Pain. 2019; 20 (1): 41.

  8. Taskapilioglu O, Karli N. Assessment of quality of life in migraine. Noro Psikiyatr Ars. 2013; 50 (Suppl 1): S60-S64.

  9. Pradilla AG, Vesga ABE, León-Sarmiento FE, Roselli DA, Bautista LE, Morillo L et al. Estudio neuroepidemiológico nacional (EPINEURO) colombiano. Rev Panam Salud Publica. 2003; 14 (2): 104-111.

  10. Morillo LE, Alarcon F, Aranaga N, Aulet S, Chapman E, Conterno L et al. Prevalence of migraine in Latin America. Headache. 2005; 45 (2): 106-117.

  11. Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A et al. Migraine. Nat Rev Dis Primers. 2022; 8 (1): 2.

  12. Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches--a narrative review. Headache. 2013; 53 (3): 437-446.

  13. Ruiz Piñero M, Mulero Carrillo P, Pedraza Hueso MI, de la Cruz Rodríguez C, López Mesonero L, Guerrero Peral AL. Bloqueo anestésico de nervios pericraneales como tratamiento preventivo de migraña: experiencia en una serie de 60 pacientes. Neurología. 2016; 31 (7): 445-451.

  14. Fernandes L, Randall M, Idrovo L. Peripheral nerve blocks for headache disorders. Pract Neurol. 2021; 21: 30-35.

  15. Ambrosini A, D'Alessio C, Magis D, Schoenen J. Targeting pericranial nerve branches to treat migraine: Current approaches and perspectives. Cephalalgia. 2015; 35 (14): 1308-1322.

  16. Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes – prolonged effects from a single injection. Pain. 2006; 122 (1): 126-129.

  17. Ashkenazi A, Matro R, Shaw JW, Abbas MA, Silberstein SD. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study. J Neurol Neurosurg Psychiatry. 2008; 79 (4): 415-417.

  18. Ashkenazi A, Young WB. The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine. Headache. 2005; 45 (4): 350-354.

  19. STROBE Statement: Available checklists [Internet]. [Citado 11 de junio de 2021]. Disponible en: https://www.strobe-statement.org/index.php?id=available-checklists

  20. Dach F, Éckeli AL, Ferreira Kdos S, Speciali JG. Nerve block for the treatment of headaches and cranial neuralgias - a practical approach. Headache. 2015; 55 Suppl 1: 59-71.

  21. Caputi CA, Firetto V. Therapeutic blockade of greater occipital and supraorbital nerves in migraine patients. Headache. 1997; 37 (3): 174-179.

  22. Inan LE, Inan N, Karadas O, Gül HL, Erdemoglu AK, Türkel Y et al. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand. 2015; 132 (4): 270-277.

  23. Miller S, Lagrata S, Matharu M. Multiple cranial nerve blocks for the transitional treatment of chronic headaches. Cephalalgia. 2019; 39 (12): 1488-1499.

  24. Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019; 99 (1): 17-24.

  25. Doane MJ, Gupta S, Vo P, Laflamme AK, Fang J. Associations between headache-free days and patient-reported outcomes among migraine patients: a cross-sectional analysis of survey data in Europe. Pain Ther. 2019; 8 (2): 203-216.

  26. Charles A. The evolution of a migraine attack - a review of recent evidence. Headache. 2013; 53 (2): 413-419.

  27. Charles A. Migraine. N Engl J Med. 2017; 377 (6): 553-561.

  28. Goadsby PJ. Pathophysiology of migraine. Ann Indian Acad Neurol. 2012; 15 (Suppl 1): S15-22.

  29. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013; 75: 365-391.

  30. Dilli E, Halker R, Vargas B, Hentz J, Radam T, Rogers R et al. Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study. Cephalalgia. 2015; 35 (11): 959-968.

  31. Becker DE. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 2013; 60 (1): 25-31; quiz 32.

  32. Giuliano C, Smalligan RD, Mitchon G, Chua M. Role of dexamethasone in the prevention of migraine recurrence in the acute care setting: a review. Postgrad Med. 2012; 124 (3): 110-115.

  33. Friedman BW, Greenwald P, Bania TC, Esses D, Hochberg M, Solorzano C et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007; 69 (22): 2038-2044.

  34. Shields KG, Levy MJ, Goadsby PJ. Alopecia and cutaneous atrophy after greater occipital nerve infiltration with corticosteroid. Neurology. 2004; 63 (11): 2193-2194.

  35. Lambru G, Lagrata S, Matharu MS. Cutaneous atrophy and alopecia after greater occipital nerve injection using triamcinolone. Headache. 2012; 52 (10): 1596-1599.

  36. Imagawa K, Ohkuma S. A case of fat injection for treating subcutaneous atrophy caused by local administration of corticosteroid. Tokai J Exp Clin Med. 2010; 35 (2): 66-69.




2020     |     www.medigraphic.com